Users can now access private company data from theJP Jenkins marketplace

Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Don't want ads? Click here
Sponsored Content
Don't want ads? Click here

Pin to quick picksIQ-AI Share News (IQAI)

Share Price Information for IQ-AI (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.835
Bid: 0.80
Ask: 0.87
Change: 0.00 (0.00%)
Spread: 0.07 (8.75%)
Open: 0.835
High: 0.835
Low: 0.835
Prev. Close: 0.835
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Timelines are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: NetScientific loss narrows; Vinanz ups Bitcoin fleet

Fri, 16th Aug 2024 20:40

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and Wednesday and not separately reported by Alliance News:

----------

NetScientific PLC - London-based life sciences focused investor - In the three months ended June, net loss narrows to USD8.3 million, or USD0.23 per basic share and diluted share from USD11.5 million, or USD0.37 a year prior. The decrease is due to lower operating expenses, company says, which fall to USD8.7 million from USD12.7 million.

----------

IQ-AI Ltd - London-based medical services company - In the half-year to June 30, says pretax loss narrows to GBP274,309 from GBP300,473. Revenue rises to GBP444,247 from GBP282,652 as do administrative expenses to GBP716,921 from GBP573,777. Believes that the years of "sustained development and innovation will, in due course, yield positive results for the company."

----------

Riverstone Credit Opportunities Inc PLC - London-based energy infrastructure and energy-transition credit investor - Plans to return around USD23.0 million to shareholders by way of a compulsory redemption of around 22.7 million shares. This is part of previously announced managed wind down process. Redemption price is USD1.017 per share.

----------

Bushveld Minerals Ltd - Vanadium producer operating the Vanchem and Vametco processing facilities in South Africa - Says South African Reserve Bank approves the applicable exchange control authorisations relating to OMF Fund III Ltd's existing security as a result of the revised funding arrangement. This is a condition of the senior loan facility agreement, announced in June. The release of additional working capital from Orion, expected to be received shortly, will provide support to execute the Vametco turnaround strategy, cover transaction costs and reduce the company's creditor balance, Bushveld explains.

----------

Vinanz Ltd - British Virgin Islands-domiciled bitcoin mining company - Increases its Bitcoin mining fleet in Nebraska by 50% with the addition of ten Bitmain Antminer S19k Pro 120 Terahash miners. Vinanz now has thirty S19k Pro 120 TH miners. Chair David Lenigas comments: "Nebraska is an important and fast-growing cluster for Vinanz's Bitcoin nexus in North America. With a power price of only 6.5 US cents per [kilo watt], Nebraska is proving to be a real winner for us when it comes to keeping operating costs low. The company is bullish on the future of Bitcoin, so further expansion into the US and Canada is our key corporate objective."

----------

Global Petroleum Ltd - Africa and Mediterranean-focused oil and gas company - Agrees to joint venture with Callum Baxter, under which Global acquires a significant interest in a mineral exploration licence located in Western Australia. Baxter was previously Chief Technical Officer of Greatland Gold PLC and was Chair and CEO of Starvest PLC. JV will be funded through a GBP600,000 placing of shares at 0.065 pence each. Global acquires initial 70% of the licence for GBP200,000. Global has a 3 month option to buy an extra 10% for GBP50,000 which would take its stake to 80%. Global will pay up to a 5% royalty on any future production from the licence.

----------

Capital Ltd - provides mining, drilling, maintenance and geochemical analysis solutions to customers within the minerals industry - Sells entire shareholding in Predictive Discovery Ltd to Perseus Mining Ltd for AUD47.3 million cash, around USD31.2 million. Says it has been an "excellent investment". Funds will help lower debt.

----------

ECR Minerals PLC - mining company focused on Australian gold projects - Announces initial gold results from soil sampling at the Lolworth project in Queensland, Australia. Says 41 soil samples returned results equal to, or greater than, 0.05 parts per million gold at the Dagwood prospect including 4 results above 1.00 ppm gold. Fifteen samples returned results greater than 0.05 ppm gold from the Gorge Creek Diggings prospect with a best result including 16.85 ppm gold. Focus now turns to the Eastern part of the tenement area to test for gold, niobium and tantalum mineralisation.

----------

Bradda Head Lithium Ltd - North American-focused lithium explorer provides drill hole geochemical results for its Basin project in Arizona - Files the complete technical report by ABH on SEDARplus for the updated mineral resource estimate at the company's Basin project asset in Arizona. The MRE is materially unchanged from that announced on July 1. The total mineral resource comprises 20 million tonnes in the measured category, Bradda says. As per the royalty agreement with the Lithium Royalty Co, the updated MRE triggers the final royalty payment of USD3.0 million, which Bradda has since requested and received.

----------

Silver Bullet Data Services Grp PLC - London-based provider of marketing services that use artificial intelligence - Secures a new contract to integrate its 4D AI technology with one of the world's largest programmatic self-service advertising buying platforms. No terms disclosed. In addition, launches 4D Mobile, an advanced contextual targeting and insights solution for privacy-first mobile advertising. Further, appoints Zeus Capital Ltd as its joint broker with immediate effect.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
3 Feb 2025 19:22

IN BRIEF: IQ-AI amends distribution deal with Blackford Analysis

IQ-AI Ltd - London-based medical services company - Amends existing distribution agreement with artificial intelligence platform provider Blackford Analysis Ltd. The amendment adds IB Nimble, IB ASL, IB FTB, and IB FTB Express to the agreement, allowing Blackford to also sell these products to their global client base. Acquired by Bayer in early 2023, Blackford operates in the healthcare AI platform and solutions sphere.

Read more
22 Jan 2025 17:10

IN BRIEF: IQ-AI to take GaM to phase II study, flags AI capabilities

IQ-AI Ltd - London-based medical services company - Provides operations update focusing on artificial intelligence. Explains radiology leads the way in Food & Drug Administration approvals for AI-enabled products as the FDA has increased efforts to keep pace with the advancements in AI technology. The company believes its subsidiary, Imaging Biometrics LLC, is in a unique position to lead this transformation for neuro-oncology in 2025 and beyond. Points to the imminent release of the new version of IB Clinic; its FDA-cleared suite of quantitative imaging solutions will include the incorporation of an AI model, which will greatly improve diagnostic accuracy and speed. In addition, notes the first half of 2025 should mark the next release of IB Nimble with the functionality to view IB's AI-generated images and other images within the mobile app. Also, in 2025 we anticipate releasing a new product leveraging arterial spin labelling.

Read more
14 Oct 2024 10:05

IN BRIEF: Braveheart buys 30% stake in IQ-AI from Braveheart CEO Brown

IQ-AI Ltd - parent of Wisconsin-based Imaging Biometrics LLC, which provides quantitative imaging platforms and therapeutics for the diagnosis and treatment of patients - AIM-listed technology investor Braveheart Investment Group PLC buys a nearly 30% stake in IQ-AI from Braveheart Chief Executive Officer Trevor Brown. Braveheart buys 45.8 million IQ-AI shares from Brown at 1.1 pence per share, worth GBP503,372, and another 19.7 million shares owned by Brown's children at the same price, worth GBP216,203. The two purchases give Braveheart a 29.5% stake in IQ-AI. Braveheart on Friday says the related-party transaction is approved by its independent shareholders because the IQ-AI business fits Braveheart's investment strategy and the purchase is at "an attractive entry price".

Read more
25 Jun 2024 11:56

IN BRIEF: IQ-AI subsidiary opens expanded access programme

IQ-AI Ltd - London-based medical services company - US-based subsidiary Imaging Biometrics LLC says that US Food & Drug Administration has approved an expanded access programme for oral gallium maltolate. This EAP will run in parallel with the current phase 1 clinical trial being conducted at the Medical College of Wisconsin. Explains that "As the phase 1 trial concludes this fall and while the data is being compiled, eligible patients in the US will have the option of participating in the EAP."

Read more
14 Jun 2024 14:32

IQ-AI team begins defining phase 2 protocol for oral gallium maltolate

(Alliance News) - IQ-AI Ltd on Friday said the clinical team has started a phase 2 protocol for its oncology-focused drug oral gallium maltolate, which could be a therapeutic agent for cancer.

Read more
23 May 2024 21:08

TRADING UPDATES: Celadon ships to US; Oxford BioDynamics-Goodbody pact

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
20 May 2024 11:16

IQ-AI subsidiary gets second FDA rare paediatric disease designation

(Alliance News) - IQ-AI Ltd on Monday said its subsidiary, Imaging Biometrics LLC, received a second rare paediatric disease designation by the US Food & Drug Administration for its IB-003 lead drug candidate oral gallium maltolate.

Read more
17 May 2024 17:39

TRADING UPDATES: Ingenta trades in line; Triple Point Social NAV up

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
10 May 2024 15:14

IQ-AI subsidiary gets rare paediatric disease designation FDA

(Alliance News) - IQ-AI Ltd on Friday said its subsidiary, Imaging Biometrics LLC, has been granted rare paediatric disease designation by the US Food & Drug Administration for its lead drug candidate, IB-003, or gallium maltolate for the treatment of ATRT.

Read more
2 May 2024 15:45

EARNINGS AND TRADING: Trident Royalties swings to profit

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
22 Feb 2024 14:02

IN BRIEF: IQ-AI shares sink on discounted placing fundraise

IQ-AI Ltd - Medical services firm and parent company of Wisconsin-based healthcare imaging software firm Imaging Biometrics LLC - Announces placing to raise GBP300,000 gross proceeds via the issue of 20.0 million new shares at a price of 1.5p each. The issue price represents a discount of 32% to the company's Wednesday closing price of 2.2p. The placing includes a broker option for existing shareholders for up to 6.7 million new shares, which would raise an additional GBP100,000. Admission of the new placing and broker option shares is expected to occur on or around March 1.

Read more
9 Feb 2024 13:38

IQ-AI subsidiary asked by FDA to resubmit and modify application

(Alliance News) - IQ-AI Ltd on Friday said its subsidiary Imaging Biometric LLC will modify and resubmit its application to the US Food & Drug Administration.

Read more
2 Feb 2024 08:56

IN BRIEF: IQ-AI celebrates USD100,000 grant for subsidiary

IQ-AI Ltd - St Helier, Jersey-based medical services firm - Says that Imaging Biometrics LLC, a wholly-owned subsidiary of IQ-AI, has been given a USD100,000 grant by the Musella Foundation For Brain Tumor Research & Information Inc. Explains that the grant will help to support the launch of an intermediate group expanded access programme, which is focused on giving brain tumour patients access to oral gallium maltolate, outside of an ongoing Phase One clinical trial at the Medical College of Wisconsin. The grant will be used to facilitate the expanded access programme, including writing and submitting the study protocol, patient screening and on-boarding.

Read more
10 Jan 2024 11:48

IQ-AI falls after subsidiary notes launch of treatment access scheme

(Alliance News) - IQ-AI Ltd shares fell on Wednesday, after it said its subsidiary Imaging Biometrics LLC is launching an intermediate population cohort expanded access programme for oral gallium maltolate.

Read more

Free Investment Tools

Register for FREE

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.